

PROGRAM



4th European Myeloma Network Meeting



Amsterdam
April 20-22, 2023

Beurs van Berlage

WELCOME MESSAGE

Dear colleagues and friends,

it is our great pleasure to invite you to attend the 4th EMN meeting – EMN2023 - that will take place in Amsterdam, from 20 to 22 April 2023.

The EMN has considerably grown in the past few years thanks to the participation and contribution of various national groups, and the success of innovative and effective clinical studies, for the benefit of our patients.

After a great start in 2018 in Italy and two subsequent virtual/ hybrid editions in 2021 and 2022, we are now very excited to finally meet you in person again. We are confident that the EMN2023 will be a great opportunity for everyone to discuss, initiate new projects and trials, and to strengthen the collaboration between national teams.

During this 3-day event, critical aspects of multiple myeloma and related diseases will be thoroughly addressed, with lively debates on controversial issues, and discussions with experts in the field. Much progress has been made in clinical research, and the EMN2023 will be a unique opportunity to share the latest news and treatment advances with everyone.

We are honored to have representatives of the various European teams, as well as colleagues from all over the world, involved in this event. The program of EMN2023 underlines our deep interest in the fundamental work of myeloma patients' associations, and our close collaboration with key scientific societies – particularly, the European Hematology Association - and companies committed to promoting new clinical trials. We are grateful for their valuable contribution and support.

The location of the EMN2023 meeting will be the Beurs van Berlage, an ideal venue to host important international congresses and big events. This historical building is right in the center of Amsterdam. Thus, you will get a chance to enjoy both the conference and the city itself, one of the most iconic, multi-cultural, and creative capitals in Europe.

Don't miss this opportunity!

We look forward to welcoming you soon.

Pieter Sonneveld & Sonja Zweegman - EMN2023 local organizers

On behalf of the Scientific Program Coordinators and the EMN Board.

SCIENTIFIC PROGRAM COORDINATORS

Pieter Sonneveld - *Local Organizer (The Netherlands)*

Sonja Zweegman - *Local Organizer (The Netherlands)*

Mario Boccardo (*Italy*)

Niels van de Donk (*The Netherlands*)

Francesca Gay (*Italy*)

Roberto Mina (*Italy*)

FACULTY

Hervé	Avet-Loiseau	Toulouse, France	Suzanne	Lentzsch	New York, USA
Meral	Beksac	Ankara, Turkey	Heinz	Ludwig	Wien, Austria
Juan	Bladé	Barcelona, Spain	Salomon	Manier	Lille, France
Mario	Boccardo	Turin, Italy	Maria-Victoria	Mateos	Salamanca, Spain
Niccolò	Bolli	Milan, Italy	Paolo	Milani	Pavia, Italy
Frank	Bridoux	Poitiers, France	Roberto	Mina	Turin, Italy
Annemiek	Broijl	Rotterdam, The Netherlands	Monique C.	Minnema	Utrecht, The Netherlands
Benedetto	Bruno	Turin, Italy	Mohamad	Mohty	Paris, France
Michele	Cavo	Bologna, Italy	Philippe	Moreau	Nantes, France
Gordon	Cook	Leeds, United Kingdom	Kate	Morgan	Brussels, Belgium
Tom	Cupedo	Amsterdam, The Netherlands	Pellegrino	Musto	Bari, Italy
Mattia	D'Agostino	Turin, Italy	Paola	Neri	Calgary, Canada
Javier	de la Rubia	Valencia, Spain	Stefania	Oliva	Turin, Italy
Michel	Delforge	Leuven, Belgium	Bruno	Paiva	Pamplona, Spain
Brian G.M.	Durie	North Hollywood, USA	Charlotte	Pawlyn	London, United Kingdom
Hermann	Einsele	Würzburg, Germany	Aurore	Perrot	Toulouse, France
Maria	Gavriatopoulou	Athens, Greece	Francesco	Pignatti	Amsterdam, The Netherlands
Francesca	Gay	Turin, Italy	Rakesh	Popat	London, United Kingdom
Sergio A.	Giralt	New York, USA	Paul	Richardson	Boston, USA
Roman	Hájek	Ostrava, Czech Republic	Paula	Rodríguez Otero	Pamplona, Spain
Jean-Luc	Harousseau	Nantes, France	Alexander	Russell-Smith	London, United Kingdom
Jesús María	Hernández Rivas	Salamanca, Spain	Hans	Scheurer	Brussels, Belgium
Alberto	Hernandez Sanchez	Salamanca, Spain	Fredrik Hellem	Schjesvold	Oslo, Norway
Jens	Hillengass	Heidelberg, Germany	Pieter	Sonneveld	Rotterdam, The Netherlands
Michael	Hudecek	Würzburg, Germany	Andrew	Spencer	Clayton, Australia
Hans	Jacobs	Nijmegen, The Netherlands	Claudia A.M.	Stege	Amsterdam, The Netherlands
Andrzej	Jakubowiak	Chicago, USA	Evangelos	Terpos	Athens, Greece
Martin	Kaiser	London, United Kingdom	Sigrun	Thorsteinsdottir	Reykjaví, Iceland
Efstathios	Kastritis	Athens, Greece	Niels	van de Donk	Amsterdam, The Netherlands
Cyrus	Khandanpour	kiel, Germany	Johannes	Waldschmidt	Würzburg, Germany
Edward	Laane	Tartu, Estonia	Katja Christina	Weisel	Hamburg, Germany
Alessandra	Larocca	Turin, Italy	Elena	Zamagni	Bologna, Italy
			Sonja	Zweegman	Amsterdam, The Netherlands

TIMETABLE

Thursday, April 20, 2023	Friday, April 21, 2023	Saturday, April 22, 2023
	08.00 - 09.00 MEET THE EXPERTS	08.00 - 09.00 MEET THE EXPERTS
9.00 - 9.10 OPENING CEREMONY	09.00 - 10.15 SESSION V NEWLY DIAGNOSED MULTIPLE MYELOMA - TRANSPLANT ELIGIBLE	09.00 - 10.05 SESSION X CLINICAL STUDIES IN PROGRESS
9.10 - 10.20 SESSION I MONOCLONAL GAMMOPATHIES OF CLINICAL SIGNIFICANCE	10.15 - 11.40 SESSION VI NEWLY DIAGNOSED MULTIPLE MYELOMA - TRANSPLANT INELIGIBLE	10.05 - 11.05 SESSION XI HARMONY - EMN JOINT SESSION
10.20 - 11.35 SESSION II MYELOMA PRECURSORS: MGUS AND SMM	11.40 - 11.55 COFFEE BREAK AND POSTER VIEWING	11.05 - 11.20 COFFEE BREAK AND POSTER VIEWING
11.35 - 11.50 COFFEE BREAK AND POSTER VIEWING	11.55 - 13.25 JANSSEN - SPONSORED SYMPOSIUM	11.20 - 12.20 SESSION XII EHA - EMN JOINT SESSION
11.50 - 13.20 BRISTOL MYERS SQUIBB - SPONSORED SYMPOSIUM	13.25 - 14.10 LUNCH AND POSTER VIEWING	12.20 - 12.50 MENARINI STEMLINE SPONSORED LECTURE
13.20 - 14.05 LUNCH AND POSTER VIEWING	14.10 - 15.35 SESSION VII TREATMENT CONSIDERATIONS AT RELAPSE	12.50 - 13.30 LUNCH AND POSTER VIEWING
14.05 - 15.40 SESSION III RISK STRATIFICATION IN MM	15.35 - 17.05 GSK - SPONSORED SYMPOSIUM	13.30 - 14.30 SESSION XIII SUPPORTIVE CARE
15.40 - 17.10 SANOFI - SPONSORED SYMPOSIUM	17.05 - 17.20 COFFEE BREAK AND POSTER VIEWING	14.30 - 15.35 SESSION XIV INTEGRATION OF IMMUNOTHERAPIES IN THE CURRENT TREATMENT LANDSCAPE
17.10 - 17.25 COFFEE BREAK AND POSTER VIEWING	17.20 - 17.50 SESSION VIII PATIENT ASSOCIATIONS	15.35 - 15.45 CONCLUSIONS AND FINAL GREETINGS
17.25 - 19.10 SESSION IV DISEASE MONITORING	17.50 - 18.45 SESSION IX THE FUTURE OF IMMUNOTHERAPIES AND THEIR DEVELOPMENT	
19.15 - 20.15 WELCOME COCKTAIL		

CONGRESS INFORMATION

VENUE

BEURS VAN BERLAGE

Damrak 243, 1012 ZJ Amsterdam
Ph +31 20 530 41 41
www.beursvanberlage.com

HOW TO REACH THE MEETING VENUE

Amsterdam Conference Centre Beurs van Berlage is located in the centre of Amsterdam, on the Damrak, directly facing Amsterdam Central Station, at a short distance of highways and Schiphol airport.

Schiphol Airport/Train

When you arrive at Amsterdam Schiphol Airport, you can reach the Beurs van Berlage by train or taxi. If you are travelling by train, you can buy a ticket to Amsterdam Centraal Station in the Arrivals Hall of Schiphol. The trains leave four times every hour and the journey takes about fifteen minutes.

If you take a taxi, you can state "Beurs van Berlage" as your destination. The address is: Damrak 243. The drive takes about twenty-five minutes.

When you arrive at Amsterdam Centraal Station by train or by tram, Beurs van Berlage is 300 metres away, about a five minute walk. You can see Beurs van Berlage on the Damrak in front of you when you leave the Central Station along the Stationsplein (Station square) and head out towards the Dam from there.

Tram/Bus

Amsterdam Conference Centre is excessable for almost every tram and bus line in Amsterdam.

You can take tram: 4, 9, 16, 24 to Damrak, which will stop 50 metres next to our building. Or take tram: 1, 2, 5, 13, 17 to Nieuwezijdsdolk which is 100 metres form our building.

Stop	Trams	Walking
Dam (Bijenkorf)	4, 9, 16, 24, 25	1 minute
Dam (Magnaplaza)	10, 13, 14, 17	5 minutes

Almost all busses and trams stop at Central station

Stop	Bus	Walking
Dam (Bijenkorf)	355, 357, 359, 361, 363	1 minute
Dam/Raadhuisstraat	170, 170, 174, 272, 352, 354, 358, N70	5 minutes

For an up-to-date timetable, go to www.gvb.nl.

By Car

The Amsterdam Conference Centre Beurs van Berlage can be reached via exit S112 on the A10. When you intent to park in the parking garage Oosterdok, you can best reach the city via exit S114. The visiting adress is Damrak 243, 1012 ZJ Amsterdam. It is not possible to park on the sidewalk in front of the main entrance.

In the immediate surroundings of Beurs van Berlage, there are a large number of carparks:

- Parking Centrum Oosterdok (9 minutes walking distance)
- Q-park parking garage De Bijenkorf (next to the Beurs van Berlage).

REGISTRATION FEES

Registration Categories	Online Registration	Onsite Registration
Standard fee	€ 350,00	€ 450,00
Participants under 35 years	€ 250,00	€ 350,00
Exhibitors *	€ 100,00	€ 150,00

* Exhibitor fee DOES NOT include: conference kit, participation in the scientific sessions.

Registration fees can be paid by credit card or by wire transfer only. Checks will not be accepted. To avoid long lines at the on-site registration counters, we encourage you to register for the meeting in advance.

The registration fee includes:

- Participation in the scientific sessions
- Access to the exhibition and poster areas
- Conference kit
- Attendance certificate
- Lunches
- Coffee breaks
- Welcome cocktail

REGISTRATION HOURS

Individuals and Exhibitors	
Wednesday, April 19, 2023	18.00 - 19.00
Thursday, April 20, 2023	08.00 - 18.00
Friday, April 21, 2023	07.30 - 18.00
Saturday, April 22, 2023	07.30 - 10.00

Groups	
Wednesday, April 19, 2023	15.00 - 19.00

BADGES

Badges and meeting materials can be collected at the counters in the registration area.

Remember to print the invitation letter and the badge barcode you received in the "Registration Info" automatic e-mail and to bring it with you.

All registered participants, speakers, sponsors and exhibitors will be given a badge which must be worn in order to be admitted to the scientific sessions.

Badge is mandatory to enter the congress area.

A self registration system will be available in the Registration Area. Delegates, sponsors and exhibitors will be able to collect their badges simply by having their personal barcode scanned by the optical reader at the self registration machines.

Speakers are kindly requested to collect their badges at the Registration desk.

The barcode on the badge stores the following personal information: name, surname, country and email address provided at the time of registration. It can be used by exhibitors to register visitors to their booths and to send additional information on their products and services.

CERTIFICATE OF ATTENDANCE

Delegates and speakers will be able to collect the certificate of attendance by having their personal barcode read at the self registration machines.

CLOAKROOM AND LUGGAGE

In the cloakroom you can leave your belongings free of charge.

The cloakroom is located in the Registration Area and will be available as follows:

Thursday, April 21, 2023	08.30 - 20.00
Friday, April 22, 2023	07.30 - 19.00
Saturday, April 23, 2023	10.00 - 16.00

CATERING

Lunches, coffee breaks and the welcome cocktail are included in the registration fee.

You will be admitted showing your badges.

The EMN Welcome Cocktail is scheduled on Thursday, April 20, 2023 from 19.00 to 20.00 in the Exhibition Area.

AUDIO - VIDEO RECORDING

Audio-video recording is prohibited.

Only authorized staff can provide audio-video recording services.

EXHIBITION AREA

Access to the exhibition area will be as follows:

Thursday, April 20, 2023	09.00 - 20.00
Friday, April 21, 2023	10.00 - 18.00
Saturday, April 22, 2023	10.00 - 14.30

OFFICIAL WEBSITE

www.emn2023.com

APP

A special mobile app has been developed for this congress.

Use the app to find sessions of interest, create your own program, find and read all the abstracts.

Download the "EMN2023" app from Apple App store or Google-Play.

SCIENTIFIC INFORMATION

LANGUAGE

Official language of the meeting is English. No simultaneous translation available.

EBAH CME CREDITS

The program of the “4th European Myeloma Network Meeting” has been reviewed and approved for CME accreditation by the European Board for Accreditation in Hematology (EBAH), an independent accreditation body endorsed by EHA. The EBAH Unit has approved this educational activity for **no. 14 CME credits** for Physicians, Biologists, Medical Laboratory Scientists and Chemists. EBAH Credit Points will be awarded for the Plenary Sessions.

To request credits, please fill out the form and return it to the registration desk at the end of the meeting.

We remind you that it is necessary to have an EBAH-CME account in order to claim for credits.

Attendees can create an EBAH-CME account registering on the website: <http://ebah.org>.

POSTER AREA

Posters will be on display in the Poster Area for three days.

Posters should be installed/removed during the indicated set-up time:

Installation	Thursday, April 20, 2023	09.00 - 12.00
Tear off	Saturday, April 22, 2023	14.00- 15.30

Materials to hang posters with will be available at the poster area. The Congress provides one board for each poster, the author is responsible for hanging and for removing the poster.

Please note that the organizers do not take any responsibility for returning uncollected material to the authors.

SLIDE CENTER AND SPEAKERS/CHAIRMEN RESERVED AREA

Opening hours:

Thursday, April 20, 2023	08.00 - 19.00
Friday, April 21, 2023	07.00 - 19.00
Saturday, April 22, 2023	07.00 - 15.00

MEET THE EXPERT SESSIONS

Meet the Expert Sessions take place on April 21 and April 22, 2023 from 8.00 to 9.00.

The registration is **Euro 20,00** per day (VAT included). This registration will not be refundable.

Each session is restricted to 30 participants.

Preregistration for these sessions is necessary. If still available, tickets can also be purchased during registration hours at the Registration Desk.

ROOM	FRIDAY, APRIL 21, 2023	SATURDAY, APRIL 22, 2023
	1 Management of patients with primary plasma cell leukemia	4 CAR-T: patients selections and management
	2 AL amyloidosis supportive care	5 Bispecifics patients selections and management
	3 SMM: practical management	

FLOOR PLAN

PROGRAM

THURSDAY, APRIL 20, 2023

09.00-09.10 **OPENING CEREMONY**

09.10-10.20 **SESSION I:
MONOCLONAL GAMMOPATHIES OF
CLINICAL SIGNIFICANCE**



Chairpersons: **S. Lentzsch, M.C. Minnema**

MGRS: diagnosis and treatment - **F. Bridoux**

Other MGCS: diagnosis and treatment - **J. Bladé**

AL amyloidosis: diagnosis - **S. Lentzsch**

AL amyloidosis upfront treatment and current and future studies - **E. Kastiris**

B01 - ORAL COMMUNICATION

VENETOCLAX TARGETED THERAPY IN AL AMYLOIDOSIS PATIENTS: A RETROSPECTIVE ANALYSIS FROM THE FRENCH AMYLOIDOSIS NETWORK
M. Roussel, M. Pirotte, R. Gounot, K. Queru, O. Rizzo, B. Royer, S. Harel, E. Desport, A. Huart, M. Niault, L. Karlin, O. Decaux, T. Chalopin, B. Carpentier, M. Macro, M. Vignon, E. Chalayer, AM. Stoppa, F. Bridoux, A. Jaccard (*Limoges-FR, Liège-BE, Créteil-FR, Bruxelles-BE, Paris-FR, Poitiers-FR, Toulouse-FR, Lorient-FR, Lyon-FR, Rennes-FR, Tours-FR, Lille-FR, Caen-FR, Saint-Etienne-FR, Marseille-FR*)

Panel discussion

10.20-11.35 **SESSION II:
MYELOMA PRECURSORS: MGUS AND SMM**



Chairpersons: **B.G.M. Durie, M.V. Mateos**

From genomics to microenvironment - **N. Bolli**

Risk-stratification of MGUS and SMM: current models vs biology-based approaches - **P. Musto**

Early detection and screening - **S. Thorsteinsdottir**

SMM: shall we treat? YES vs NO - **M.V. Mateos vs M. Boccadoro**

SMM: ongoing trials and trials we need - **B.G.M. Durie**

Panel discussion

11.35-11.50 Coffee break and poster viewing

11.50-13.20 **BRISTOL MYERS SQUIBB SPONSORED SYMPOSIUM**

Details pag. 27

13.20-14.05 Lunch and poster viewing

14.05-15.40 **SESSION III:
RISK STRATIFICATION IN MM**



Chairpersons: **H. Avet-Loiseau, P. Sonneveld**

How to define high risk MM in 2023? - **M. D'Agostino**

High risk FISH harmonization - **H. Avet-Loiseau**

Shall CTC be incorporated in high risk definition? - **B. Paiva**

Extramedullary disease - **M. Beksac**

Can new immunotherapies overcome HR? - **A. Perrot**

New trials and concept for HRMM - **M. Kaiser**

B02 - ORAL COMMUNICATION

CARFILZOMIB AND LENALIDOMIDE-BASED THERAPY FOR THE TREATMENT OF PRIMARY PLASMA CELL LEUKEMIA: RESULTS OF THE FINAL ANALYSIS OF THE PROSPECTIVE PHASE 2 EMN12/HOVON-129 STUDY FOR PATIENTS AGED 18-65 YEARS

N.W.C.J. van de Donk, M.C. Minnema, B. van der Holt, F. Schjesvold, K.L. Wu, A. Capra, A. Broyl, W.W.H. Roeloffzen, A.P.A. Gadisseur, G. Pietrantonio, L. Pour, V. van der Velden, T. Lund, M. Offidani, M. Grasso, L. Giaccone, M. Cavo, T. Silkjaer, J. Caers, S. Zweegman, R. Hajek, R. Benjamin, A. Vangsted, M. Boccadoro, F. Gay, P. Sonneveld, P. Musto (*Amsterdam-NL, Utrecht-NL, Rotterdam-NL, Oslo-NO, Antwerp-BE, Torino-IT, Groningen-NL, Edegem-BE, Rionero in Vulture-IT, Brno-CZ, Odense-DK, Ancona-IT, Cuneo-IT, Bologna-IT, Aarhus-DK, Liege-BE, Ostrava-CZ, London-UK, Copenhagen-DK, Bari-IT*)

B03 - ORAL COMMUNICATION

CARFILZOMIB AND LENALIDOMIDE FOR PRIMARY PLASMA CELL
LEUKEMIA: FINAL RESULTS OF THE PROSPECTIVE PHASE 2
EMN12/HO VON-129 STUDY FOR PATIENTS AGED ≥66 YEARS

P. Musto, M.C. Minnema, W.W.H. Roeloffzen, A. Capra, B. van der Holt,
A. Juul Vangsted, A. Broyl, F. Schjesvold, T. Lund, T. Silkjaer, R. Benjamin, M. Grasso,
K. Lung Wu, J. Caers, M. Cavo, R. Hájek, B. Bruno, A. Gadisseur, G. Pietrantuono,
M. Offidani, L. Pour, P. Sonneveld, M. Boccadoro, N. van de Donk (Bari-IT, Utrecht-NL,
Groningen -NL, Torino-(IT), Rotterdam-NL, Copenhagen-DK, Oslo-NO, Odense-DK,
Aarhus-DK, London-UK, Cuneo -IT, Antwerp-BE), Liege-BE, Bologna -IT, Edegem-BE,
Rionero in Vulture-IT, Ancona-IT, Brno-CZ, Amsterdam-NL)

Panel discussion

B04 - ORAL COMMUNICATION

IMPLEMENTING M-PROTEIN DIAGNOSTICS IN MULTIPLE MYELOMA
PATIENTS USING ULTRA-SENSITIVE TARGETED MASS SPECTROMETRY DATA
AND AN OFF-THE-SHELF CALIBRATOR

C. Wijnands, P. Langerhorst, S. Noori, J. Gloerich, V. Bonifay, C. Touzeau, J. Corre,
A. Perrot, P. Moreau, H. Caillon, T. Luider, A. van Gool, T. Dejoie, M. VanDuijn,
J. Jacobs (Nijmegen-NL, Rotterdam-NL, Nijmegen-NL, Lisses-FR, Nantes-FR,
Toulouse-FR, Nantes-FR)

Panel discussion

19.15

WELCOME COCKTAIL

15.40-17.10 **SANOFI SPONSORED SYMPOSIUM**

Details pag. 27

17:10-17:25 Coffee break and poster viewing

17.25-19.10 **SESSION IV:
DISEASE MONITORING**



Chairpersons: P. Moreau, A. Spencer

MRD imaging monitoring: PET/CT vs MRI - **E. Zamagni vs J. Hillengass**

Bone marrow vs peripheral blood monitoring (mass spect) - **S. Oliva vs H. Jacobs**

Can we use MRD for treatment decisions? YES vs NO - **M. Kaiser vs K.C. Weisel**

MRD driven strategies: key ongoing and future trials - **B. Paiva**

Experimental disease monitoring in EMN correlative studies - **T. Cupedo**

FRIDAY, APRIL 21, 2023

08.00-09.00 MEET THE EXPERTS

Simultaneous sessions in three rooms

1. Management of patients with primary plasma cell leukemia
F. Gay, N. van de Donk
2. AL amyloidosis supportive care
P. Milani, M.C. Minnema
3. SMM: practical management
M.V. Mateos, P. Musto

09.00-10.15 SESSION V:

NEWLY DIAGNOSED MULTIPLE MYELOMA - TRANSPLANT ELIGIBLE

Chairpersons: M. Cavo, P. Moreau

Treatment algorithm for TE patients - **P. Moreau**

Debate: Upfront vs delayed ASCT - **F. Gay vs S.A. Giralt**

Single vs double ASCT in the era of quadruplets - **M. Cavo**

How to tailor therapy in HR patients - **R. Mina**

B05 - ORAL COMMUNICATION

PLASMA CELL LEUKEMIA-LIKE STATUS HAS INDEPENDENT PROGNOSTIC VALUE IN THE CONTEXT OF THE SECOND REVISION OF THE INTERNATIONAL STAGING SYSTEM

D. Hofste op Bruinink, R. Kuiper, M. van Duin, T. Cupedo, V. van der Velden, R. Hoogenboezem, B. van der Holt, B. Beverloo, E. Valent, M. Vermeulen, M. D'Agostino, F. Gay, A. Broijl, H. Avet-Loiseau, N. Munshi, P. Musto, P. Moreau, S. Zweegman, N. van de Donk, P. Sonneveld (*Rotterdam-NL, Torino-IT, Toulouse-FR, Boston-USA, Bari-IT, Nantes-FR, Amsterdam-NL*)

Panel discussion



10.15-11.40

SESSION VI:

NEWLY DIAGNOSED MULTIPLE MYELOMA - TRANSPLANT INELIGIBLE

Chairpersons: G. Cook, S. Manier

Frailty assessment: YES vs NO - **A. Larocca vs S. Manier**

Treatment options in TIE patients - **M.V. Mateos**

Treatment of unfit and frail patients - **C.A.M. Stege**

What trials do we need in frail patients? - **S. Zweegman**



B06 - ORAL COMMUNICATION

HIGH LEVELS OF CIRCULATING PLASMA CELLS AT DIAGNOSIS ARE PREDICTIVE FOR WORSE PROGNOSIS IN BOTH TRANSPLANT-ELIGIBLE AND -INELIGIBLE PATIENTS WITH MULTIPLE MYELOMA

P. Malandrakis, I. Ntanasis-Stathopoulos, I.V. Kostopoulos, P. Roussakis, E. Eleutherakis-Papaïakovou, C. Panteli, N. Angelis, V. Spiliopoulou, N. Orolagas-Stavrou, F. Theodorakakou, D. Fotiou, M. Migkou, M. Gavriatopoulou, E. Kastritis, O.E. Tsitsilonis, M.A. Dimopoulos, E. Terpos (*Athens-GR*)

B07 - ORAL COMMUNICATION

HIGH EXPRESSION OF NUCLEAR CEREBLON IS ASSOCIATED WITH LONGER SURVIVAL IN PATIENTS WITH MULTIPLE MYELOMA TREATED WITH IMiDS

R. Wester, M. van Duin, K.H. Lam, S.S. Couto, Y. Ren, M. Wang, T. Cupedo, B. van der Holt, H.B. Beverloo, A.L. Nigg, A. Thakurta, A.A. Waage, S. Zweegman, A. Broijl, P. Sonneveld (*Rotterdam-NL, Princeton-USA, San Diego-USA, Summit-USA, Trondheim-NL, Amsterdam-NL*)

Panel discussion

11.40-11.55 Coffee break and poster viewing

11.55-13.25 JANSSEN SPONSORED SYMPOSIUM

Details pag. 28

13.25-14.10 Lunch and poster viewing

14.10-15.35

**SESSION VII:
TREATMENT CONSIDERATIONS AT RELAPSE**



Chairpersons: C. Pawlyn, E. Terpos

Treatment options at first relapse - P. Sonneveld

Treatment options at second relapse - P. Rodríguez-Otero

Treatment of triple-class refractory disease: immunotherapy - A. Broijl

Treatment of triple-class refractory disease: beyond immunotherapy - M. Gavriatopoulou

Post BCMA relapse: how to approach - M. Mohty

B08 - ORAL COMMUNICATION

IDECABTAGENE VICLEUCEL VERSUS STANDARD REGIMENS IN PATIENTS WITH TRIPLE-CLASS-EXPOSED RELAPSED AND REFRACTORY MULTIPLE MYELOMA: KARMMA-3 A PHASE 3 RANDOMIZED CONTROLLED TRIAL

P. Rodríguez-Otero, S. Ailawadhi, B. Arnulf, K. Patel, M. Cavo, A.K. Nooka, S. Manier, N. Callander, L.J. Costa, R. Vij, N.J. Bahlis, P. Moreau, S.R. Solomon, M. Delforge, J. Berdeja, A. Truppel-Hartmann, Z. Yang, L. Favre-Kontula, F. Wu, J. Piasecki, M. Cook, S. Giralat (Pamplona-ES, Jacksonville-USA, Paris-FR, Houston-USA, Bologna-IT, Atlanta-USA, Lille-FR, Madison-USA, Birmingham-USA, Saint Louis-USA, Calgary-CAN, Nantes-FR, Leuven-BE, Nashville-USA, Cambridge-USA, Princeton-USA, New York-USA)

B09 - ORAL COMMUNICATION

CARTITUDE-2 COHORT B 18-MONTH FOLLOW-UP: CILTACABTAGENE AUTOLEUCEL (CILTA-CEL), A BCMA-DIRECTED CAR-T CELL THERAPY, IN PATIENTS WITH MULTIPLE MYELOMA (MM) AND EARLY RELAPSE AFTER INITIAL THERAPY

S. Zweegman, M. Agha, A.D. Cohen, Y.C. Cohen, S. Anguille, T. Kerre, W. Roeloffzen, D. Madduri, J.M. Schechter, K.C. De Braganca, C.C. Jackson, H. Varsos, P. Mistry, T. Rocca, X. Xu, K. Li, E. Zudaire, C. Corsale, M. Akram, D. Geng, L. Pacaud, P. Sonneveld, N.W.C.J. van de Donk (Amsterdam-NL, Pittsburgh-USA, Philadelphia-USA, Tel Aviv-IL, Edegem-BE, Ghent-BE, Groningen-NL, New York-USA, Raritan-USA, High Wycombe-UK, Raritan-USA, Spring House-USA, Piscataway-USA, Rotterdam-NL)

Panel discussion

15.35-17.05 **GSK SPONSORED SYMPOSIUM**

Details pag. 28

17.05-17.20 Coffee break and poster viewing

17.20-17.50 **SESSION VIII:
PATIENT ASSOCIATIONS**



Chairpersons: M. Boccadoro, B.G.M. Durie

Projects and perspective of the IMF - B.G.M. Durie

Access to treatment in Europe: MPE perspective - K. Morgan

Panel discussion

17.50-18.45 **SESSION IX:
THE FUTURE OF IMMUNOTHERAPIES AND
THEIR DEVELOPMENT**



Chairpersons: B. Bruno, H. Einsele

CAR-T - M. Hudecek

T cell engagers - N. van de Donk

ADC - E. Terpos

Newer immunotherapeutic modalities - R. Popat

Panel discussion

SATURDAY, APRIL 22, 2023

08.00-09.00 MEET THE EXPERTS

Simultaneous sessions in two rooms

- CAR-T: patients selections and management
R. Mina, J. Waldschmidt
- Bispecifics patients selections and management
A. Jakubowiak, F.H. Schjesvold

09.00-10.05 SESSION X: CLINICAL STUDIES IN PROGRESS

Chairpersons: G. Cook, P. Moreau

NDMM - **P. Sonneveld**

RRMM - **P. Richardson**

What kind of trials do we need in the future? - **J.L. Harousseau**

Panel discussion



10.05-11.05 SESSION XI: HARMONY - EMN JOINT SESSION Big Data innovations in Multiple Myeloma: New analytic tools and new insights

Chairpersons: J.M. Hernández Rivas, P. Sonneveld

Update and latest achievements

Update and outlook HARMONY Alliance:

Big Data for Hematology - **J.M. Hernández Rivas**

Scientific achievements in AML with

the HARMONY Big Data Platform - **A. Hernández Sánchez**

Scientific achievements in MM Research Projects working with

the MM data lake - **M. D'Agostino, A. Russell-Smith**

*Opportunities for continued collaboration focusing on collecting
PROMS and PREMS:*

The added value of including PROMs/PREMs data
in research projects - **H. Ludwig**

HARMONY Alliance QoL research project - **H. Scheuer**

GROTE ZAAL

11.05-11.20 Coffee break and poster viewing

11.20-12.20 SESSION XII: EHA - EMN JOINT SESSION

Chairpersons: H. Einsele, S. Zweegman

Regulator's perspective - **F. Pignatti**

Clinician's perspective - **E. Laane**

Patient's perspective - **H. Scheurer**

Panel discussion



12.20-12.50 MENARINI STEMLINE SPONSORED LECTURE

Details pag. 28

12.50-13.30 LUNCH and POSTER VIEWING

13.30-14.30 SESSION XIII: SUPPORTIVE CARE

Chairpersons: H. Ludwig, P. Neri

Infections and prophylaxis - **H. Ludwig**

Covid 19 and myeloma - **H. Ludwig**

Management of T-Cell immunotherapy toxicity - **M. Delforge**

Bone disease - **E. Terpos**

Panel discussion



14.30-15.35 SESSION XIV: INTEGRATION OF IMMUNOTHERAPIES IN THE CURRENT TREATMENT LANDSCAPE

Chairpersons: M. Boccadoro, S. Zweegman

How to tailor immunotherapy - **P. Neri**

Anti-BCMA retreatment vs antigen switch - **R. Popat vs R. Hájek**

Mechanisms of CART/bispecifics/ADC resistance - **N. van de Donk**

How to harness new immunotherapies with combination strategies? - **H. Einsele**

Panel discussion



15.35-15.45 CONCLUSIONS AND FINAL GREETINGS

SPONSORED SYMPOSIA AND LECTURE

Thursday, April 20, 2023

- 11.50-13.20 **BRISTOL MYERS SQUIBB SPONSORED SYMPOSIUM** GROTE ZAAL
Advancements in the treatment of MM: overview of treatment options covering latest developments
Chairperson: N. van de Donk
- Introduction - **N. van de Donk**
 Evolving standard of care options for NDMM and RRMM patients - **P. Moreau**
 Emerging preclinical/clinical data from novel CELMoD™ agents - **N. van de Donk**
 Where do we stand and where do we go next with CAR-T cell therapy:
 an update on novel developments - **M. Delforge**
 Emerging immune-based therapies for RRMM:
 new targets and new modalities - **K. Weisel**
 Q&A session
- 15.40-17.10 **SANOFI SPONSORED SYMPOSIUM** GROTE ZAAL
A voyage of discovery: Exploring the latest evidence for 1q21+
Chairperson: M. Kaiser
- Welcome and introduction - **M. Kaiser**
 Recalibrating high risk: does 1q21+ refine the barometer? - **M. D'Agostino**
 Round table discussion of data: How do we assess patient risk
 and where does 1q21+ fit into this? - **C. Khandanpour**
 A wealth of knowledge: translating evidence to the clinic
 Round table discussion:
 Testing and treatment of patients with 1q21+ in clinical practice - **M. D'Agostino**
 A new part of the map: Navigating the evidence for treating 1q21+
 Round table discussion: Treatment of 1q21+ patients and the view
 on efficacy of anti-CD38 as class effect - **M. Kaiser**
 Panel discussion

Friday, April 21, 2023

- 11.55-13.25 **JANSSEN SPONSORED SYMPOSIUM** GROTE ZAAL
Precision medicine: Individualizing treatment selection in multiple myeloma
Chairperson: M. Minnema
- Introduction - **M. Minnema**
 Frontline therapy for elderly / frail patients with MM - **G. Cook**
 Selecting T-cell redirecting therapies for patients with MM - **H. Einsele**
 Effective management strategies for T-cell
 redirecting therapies in patients with MM - **E. Zamagni**
 Panel discussion
- 15.35-17.05 **GSK SPONSORED SYMPOSIUM** GROTE ZAAL
Future treatment landscape and addressing difficult to treat populations in the light of anti-BCMA treatments
Chairperson: P. Sonneveld
- New advances in anti-BCMA treatment in RRMM - **H. Einsele**
 Anti-BCMA sequencing: what we know and what has to be done - **F. Gay**
 Renal impairment management - **J. de la Rubia**
 High risk patients: what's new in 2023? - **P. Sonneveld**
 Discussion and closing remarks

Saturday, April 22, 2023

- 12.20-12.50 **MENARINI STEMLINE SPONSORED LECTURE** GROTE ZAAL
Change of MoA after monoclonal antibody exposure: the role of XPO1 in Multiple Myeloma today
M. Merz, E. Terpos

POSTER

POSTER

1. BIOLOGY AND PRECLINICAL

P01

LACTATE TRAFFICKING INHIBITION RESTORES SENSITIVITY TO PROTEASOME INHIBITORS AND ORCHESTRATES IMMUNOMICROENVIRONMENT IN MULTIPLE MYELOMA
C. Giallongo, T. Zuppelli, G. Scandura, E. La Spina, I. Dulcamare, D. Cambria, S. Giallongo, A. Romano, N. Parrinello, V. Del Fabro, M. Aguennoz, G. Li Volti, G.A. Palumbo, F. Di Raimondo, D. Tibullo (Catania, Messina-IT)

P02

ARGININE DEPRIVATION INDUCES ACQUISITION OF A SENESCENT PHENOTYPE AND FAVORS GENOMIC INSTABILITY IN MULTIPLE MYELOMA PLASMACELLS
A. Romano, G. Scandura, C. Giallongo, E. La Spina, S. Giallongo, L. Longhitano, T. Zuppelli, I. Dulcamare, N.L. Parrinello, F. Polito, R. Oteri, M. Aguenouz, N. Vicario, A.M. Amorini, V. Del Fabro, C. Conticello, G. Li Volti, G.A. Palumbo, D. Tibullo, F. Di Raimondo (Catania, Messina-IT)

P03

COMBINING SKY92 GENE EXPRESSION PROFILING AND IGH CLONALITY TO EVALUATE GENETIC RISK IN IRISH MULTIPLE MYELOMA PATIENTS
R. McAvera, I. Drozd, H. Black, T. Cichocka, E. Szegezdi, J. Quinn, P. Murphy, P. Thornton, M. Perera, R. Clifford, N. Keane, V. Mykytiv, E. Elhassadi, R. Cummins, M. O'Dwyer, S. Glavey (Dublin-IE, Galway-IE, Tullamore-IE, Limerick-IE, Cork-IE, Waterford-IE)

P04

MULTIPARAMETRIC FLOW CYTOMETRY REFINES RISK STRATIFICATION IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS
F. Fazio, G. Lapietra, M. Z. Limongi, S. Intoppa, M.L. Milani, A. Piciocchi, M. Martelli, A. Guarini, R. Foà, M.S. De Propriis, M.T. Petrucci (Roma-IT)

P05

ACETYL SALICYLIC ACID INDUCES POLARIZATION OF MACROPHAGES AND CYTOTOXICITY ON MYELOMA CELLS IN VITRO
N. Gonulkirmaz, M. Beksac, T. Ozkan, I. Kar, A. Sunguroglu (Ankara-TR)

P06

MODELING DYNAMIC EVOLUTION OF MULTIPLE MYELOMA STUDYING CELL POPULATIONS METABOLISM AND COMPETITION UNDER MAXIMUM POWER CONSTRAINTS: A SYSTEMS-THINKING BASED APPROACH
A. Romano, L. Conte, A. Giansanti, A. Kleidon, F. Gonella (Catania, Venezia, Roma-IT, Jena-DE)

2. NEWLY DIAGNOSED MULTIPLE MYELOMA

P07

BORTEZOMIB-MELPHALAN-PREDNISONE (VMP) VS. LENALIDOMIDE-DEXAMETHASONE (RD) IN REAL-LIFE MULTIPLE MYELOMA PATIENTS INELIGIBLE FOR TRANSPLANT: UPDATED ANALYSIS OF THE RANDOMIZED PHASE IV REAL MM TRIAL
A. Larocca, M. D'Agostino, N. Giuliani, E. Antonioli, R. Zambello, S. Ronconi, I.D. Vincelli, F. Ciceri, A.P. Falcone, M. Michieli, F. Cattel, A. Capra, M. Grasso A.M. Cafro, F. Bonello, R. Floris, M. Offidani, E. Sciorsi, G. Pietrantuono, P. Curci, F. Patriarca, M. Cavo, S. Mangiacavalli, G. Benevolo, A. Evangelista, G. Ciccone, M. Boccadoro, B. Bruno, S. Bringhen (Torino, Parma, Firenze, Padova, Meldola, Reggio Calabria, Milano, San Giovanni Rotondo, Aviano, Cuneo, Cagliari, Ancona, Rionero in Vulture, Bari, Udine, Bologna, Pavia-IT)

P08

TEMPORAL TRENDS IN PROGNOSIS OF PATIENTS WITH SMOLDERING MULTIPLE MYELOMA (SMM) WHO MEET CRITERIA FOR BIOMARKER-DEFINED EARLY MULTIPLE MYELOMA (SLIM CRAB POSITIVE MM)
H. Ludwig, S. Kainz, N. Zojer, M. Schreder, A. Hinke (Vienna-AT, Düsseldorf-DE)

P09

DARATUMUMAB PLUS LENALIDOMIDE AND DEXAMETHASONE (D-RD) VERSUS LENALIDOMIDE AND DEXAMETHASONE (RD) ALONE IN TRANSPLANT-INELIGIBLE PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM): UPDATED ANALYSIS OF THE PHASE 3 MAIA STUDY
K. Weisel, S. Kumar, P. Moreau, N. Bahlis, T. Facon, T. Plesner, R. Orłowski, S. Basu, H. Nahi, C. Hulin, H. Quach, H. Goldschmidt, M. O'Dwyer, A. Perrot, C. Venner, N. Raje, M. Tiab, M. Macro, L. Frenzel, X. Leleu, H. Pei, M. Krevvata, R. Carson, F. Borgsten, S. Usmani (Hamburg-DE, Rochester-USA, Nantes-FR, Calgary-CAN, Lille-FR, Vejle-DK, Houston-USA, Wolverhampton-UK, Stockholm-SE, Pessac-FR, Melbourne-AUS, Heidelberg-DE, Galway-IE, Toulouse-FR, Edmonton-CAN, Vancouver-CAN, Boston-USA, La Roche sur Yon-FR, Caen-FR, Paris-FR, Poitiers-FR, Titusville-FL, Spring House-USA, Raritan-USA, New York-USA)

P10

AN ULTRA-SENSITIVE METHOD FOR SEQUENCING AND MONITORING OF M-PROTEIN IN PERIPHERAL BLOOD (M-INSIGHT)
V. Bonifay, V. Vimard, S. Noori, C. Wijnands, C. Touzeau, J. Corre, A. Perrot, P. Moreau, H. Caillon, T. Dejoie, T. Luider, M. VanDuijn, J. Jacobs, A. Van Gool, P. Sonigo (Lisses-FR, Rotterdam-NL, Nijmegen-NL, Nantes-FR, Toulouse-FR)

P11

COMBINED DIFFUSION WEIGHTED WHOLE BODY MRI (DW-MRI) AND MULTIPARAMETRIC FLOW CYTOMETRY (MFC) EVALUATION FOR MINIMAL RESIDUAL DISEASE DETECTION IN MULTIPLE MYELOMA PATIENTS: CONCORDANCE ANALYSIS OF THE TWO TECHNIQUES AND PREDICTIVE ROLE AFTER TRANSPLANT

A. Belotti, R. Ribolla, C. Crippa, M. Chiarini, V. Giustini, S. Ferrari, A. Peli, C. Cattaneo, A. Roccaro, B. Frittoli, L. Grazioli, G. Rossi, A. Tucci (*Brescia-IT*)

P12

HEALTH-RELATED QUALITY OF LIFE IN FRAIL AND INTERMEDIATE-FIT PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA TREATED WITH DOSE-ADJUSTED MELPHALAN-PREDNISONE-BORTEZOMIB (MPV)

M.R. Seefat, C.A.M. Stege, G.J. Timmers, M.D. Levin, M. Hoogendoorn, P.F. Ypma, I.S. Nijhof, G.A. Velders, L. Strobbe, N. Durdu-Rayman, M. Westerman, M.A. Davidis-van Schoonhoven, R.J.W. van Kampen, A. Beeker, A. Koster, A.C. Dijk, N.W.C.J. van de Donk, E. van der Spek, M.B.L. Leys, M.H. Silbermann, K. Groen, N.C.H.P. van der Burg-de Graauw, H.A.M. Sinnige, K.G. van der Hem, T.H. Levenga, Y.M. Bilgin, P. Sonneveld, S.K. Klein, K. Nasserinejad, H.M. Blommestein, D.G.J. Cucchi, B.I. Lissenberg-Witte, S. Zweegman (*Amsterdam-NL, Amstelveen-NL, Dordrecht-NL, Leeuwarden-NL, Den Haag-NL, Ede-NL, Zutphen-NL, Schiedam-NL, Alkmaar-NL, Gorinchem-NL, Sittard-Geleen-NL, Hoofddorp-NL, Venlo-NL, Harderwijk-NL, Arnhem-NL, Rotterdam-NL, Hilversum-NL, Roosendaal-NL, Den Bosch-NL, Zaandam-NL, Gouda-NL, Goes-NL, Amersfoort-NL*)

P13

IXAZOMIB, DARATUMUMAB AND LOW-DOSE DEXAMETHASONE IN INTERMEDIATE-FIT PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA; RESULTS OF THE INDUCTION AND MAINTENANCE TREATMENT OF THE PHASE II HOVON 143 STUDY

K. Groen, C. Stege, K. Nasserinejad, K. de Heer, R. van Kampen, R. Leys, N. Thielen, M. Westerman, K. Wu, I. Ludwig, D. Issa, G. Velders, M. Vekemans, N. van de Donk, G. Timmers, F. de Boer, L. Tick, E. van der Spek, E. de Waal, M. Sohne, P. Sonneveld, I. Nijhof, S. Klein, M. Levin, P. Ypma, S. Zweegman (*Amsterdam-NL, Rotterdam-NL, Almere-NL, Sittard-Geleen-NL, Rotterdam-NL, Utrecht-NL, Alkmaar-NL, Antwerpen-BE, Uden-NL, Den Bosch-NL, Ede-NL, Brussels-BE, Amstelveen-NL, Eindhoven-NL, Arnhem-NL, Leeuwarden-NL, Nieuwegein-NL, Amersfoort-NL, Groningen-NL, Dordrecht-NL, Den Haag-NL*)

P14

OCULAR TOXICITY IN TRANSPLANT INELIGIBLE PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA TREATED WITH BELANTAMAB MAFODOTIN, LENALIDOMIDE AND DEXAMETHASONE IN A PHASE 1/2 TRIAL

I. Ntanas-Stathopoulos, M. Gavriatopoulou, P. Malandrakis, D. Fotiou, N. Kanellias, M. Migkou, F. Theodorakakou, V. Spiliopoulou, R. Syrigou, E. Eleutherakis-Papaiakovou, S. Gkolfinopoulos, K. Manousou, E. Kastritis, M.A. Dimopoulos, E. Terpos (*Athens-GR, Dublin-IR*)

P15

VALIDATION OF THE NOVEL EUROPEAN MYELOMA NETWORK PROGNOSTIC SCORE (R2-ISS) IN AN INDEPENDENT REAL-WORLD SETTING

G. Cengiz Seval, M. Aydogan, M.H. Akbulut, B. Karakaya, G. Yavuz, H. Yilmaz, M. Beksac (*Ankara-TR*)

P16

HEALTH-RELATED QUALITY OF LIFE FOR FRAIL TRANSPLANT-INELIGIBLE PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA TREATED WITH DARATUMUMAB, LENALIDOMIDE AND DEXAMETHASONE: SUBGROUP ANALYSIS OF MAIA TRIAL

T. Facon, T. Plesner, S. Usmani, S. Kumar, N. Bahlis, C. Hulin, R. Orłowski, H. Nahi, P. Mollee, K. Ramasamy, M. Roussel, A. Jaccard, M. Delforge, L. Karlin, B. Arnulf, A. Chari, H. Pei, N. Gupta, S. Kaila, K. Matt, K. Gries, R. Carson, F. Borgsten, K. Weisel, A. Perrot (*Lille-FR, Vejle-DK, New York-USA, Rochester-USA, Calgary-CAN, Pessac-FR, Houston-TX, Stockholm-SE, Woolloongabba-AUS, Oxford-UK, Limoges-FR, Leuven-FR, Lyon-FR, Paris-FR, Titusville-USA, Horsham-UK, Raritan-USA, Hamburg-DE, Toulouse-FR*)

P17

CLONAL PLASMA-CELLS IN STEM CELL APHERESIS AS A PREDICTOR OF PROGRESSION IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS ELEGIBLE FOR AUTOLOGOUS STEM CELL TRANSPLANTATION

S. Pileri, I. Attucci, L. Pengue, B. Peruzzi, R. Caporale, S. Bencini, M. Messeri, A. Buzzichelli, Vannucchi, E. Antonioli (*Firenze-IT*)

P18

SKIN EXPRESSION OF P16^[^]JNK4A^[^], A BIOMARKER FOR CELLULAR SENESCENCE, DOES NOT PREDICT FRAILTY OR TREATMENT OUTCOME IN NEWLY DIAGNOSED MULTIPLE MYELOMA

F. Smits, K. Groen, C. Stege, M. Seefat, I. Nijhof, N. van de Donk, P. Ypma, S. Zweegman (*Amsterdam-NL, Nieuwegein-NL, Den Haag-NL*)

P19

EXTERNAL VALIDATION OF THREE EXISTING EARLY MYELOMA RELAPSE SCORES (BY EBMT, CIBMTR, AND GIMEMA) IN A SINGLE CENTER SHOWS MAJOR DIFFERENCES

M. Beksac, G. Cengiz Seval, S. Civriz Bozdog, S.K. Toprak, M. Kurt Yuksel, P. Topcuoglu, O. Arslan, M. Ozcan, T. Demirer, O. Ilhan, G. Gurman (*Ankara-TR*)

P20

LENALIDOMIDE MAINTENANCE AFTER VTD INDUCTION AND AUTOLOGOUS STEM CELL TRANSPLANTATION: PRELIMINARY RESULTS OF A REAL-LIFE STUDY INCLUDING 389 PATIENTS

G. Barilà, A. Pascarella, C. Conticello, R. Mina, C. Marcon, F. Fazio, C. Cartia, G. Buda, S. Pileri, S. Rocchi, A. Maroccia, N. Sgherza, M. Porrizzo, N. Pescosta, A. Furlan, E. Scomazzon, G. Mele, M. Gentile, M.L. Del Giudice, G. Schininà, L. Pavan, G. De Cicco, A. Casson, C. Lisi, E. Antonioli, S. Mangiacavalli, P. Musto, F. Gay, E. Zamagni, M.T. Petrucci, F. Di Raimondo, F. Patriarca, R. Bassan, R. Zambello (*Venezia, Catania, Torino, Udine, Roma, Pavia, Pisa, Firenze, Bologna, Padova, Bari, Trieste, Bolzano, Treviso, Vicenza, Brindisi, Cosenza-IT*)

P21

EFFECTIVENESS AND SAFETY OF DELAYED BORTEZOMIB, THALIDOMIDE AND DEXAMETHASONE (VTD) REGIMEN

V. Del Fabro, G. Schininà, G. Sapuppo, G. Uccello, M. Gentile, F. Palumbo, A. Romano, F. Di Raimondo, C. Conticello (*Catania-IT*)

P22

THE PROGNOSTIC ROLE OF 1Q ABNORMALITIES IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS

I. Attucci, S. Pileri, S. Bonifacio, L. Pengue, A. Buzzichelli, M. Messeri, A.M. Vannucchi, E. Antonioli (*Firenze-IT*)

P23

EMAGINE/CARTITUDE-6: A RANDOMIZED PHASE 3 STUDY OF DVRD FOLLOWED BY CILTACABTAGENE AUTOLEUCEL VERSUS DVRD FOLLOWED BY AUTOLOGOUS STEM CELL TRANSPLANT IN TRANSPLANT-ELIGIBLE PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA

A. Broijl, J. San-Miguel, K. Suzuki, A. Krishnan, N. van de Donk, G. Cook, A. Jakubowiak, D. Madduri, S. Afifi, A. Stevens, J. Schecter, W. Deraedt, S. Kuppens, P. Mistry, L. Pacaud, M. Boccadoro, F. Gay, R. Mina, L. Rasche, P. Moreau, M. Mateos, H. Einsele, P. Sonneveld (*Rotterdam-NL, Pamplona-ES, Tokyo-JP, Duarte-USA, Amsterdam-NL, Leeds-UK, Chicago-USA, Raritan-USA, Beerse-BE, High Wycombe-UK, Piscataway-USA, Torino-IT, Würzburg-DE, Nantes-FR, Salamanca-ES*)

P24

HIGH-DOSE CYCLOPHOSPHAMIDE 4 GR/M2 AND STEM-CELL COLLECTION AFTER DARATUMUMAB-BASED QUADRUPLET INDUCTION IN NEWLY DIAGNOSED TRANSPLANT-ELIGIBLE MULTIPLE MYELOMA PATIENTS: A SINGLE-CENTER EXPERIENCE

C. Liberatore, C. Passeri, F. Fioritoni, O. Iuliani, G. Montanaro, A. Di Nicola, P. Accorsi, S. Santarone, S. Pulini, M. Di Ianni (*Pescara, Chieti-IT*)

P25

EFFECT OF DARATUMUMAB ON STEM CELL YIELDS IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA: REPORT FROM THE MULTIPLE MYELOMA LAZIO GROUP

F. Fazio, M. Passucci, C. Lisi, J. Micozzi, L. Fianchi, F. Di Landro, T. Za, S. Gumenyuk, S. Ferraro, B. Anaclerico, L. De Padua, O. Annibali, A. Rago, A. Piciocchi, V. Bongarzone, L. Cupelli, A. Mengarelli, V. De Stefano, M. Martelli, M.T. Petrucci (*Roma, Frosinone-IT*)

P26

LANDSCAPE OF RECURRENT CYTOGENETIC ABNORMALITIES IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA AS DETECTED BY CHROMOSOME MICROARRAY ANALYSIS (CMA)

A. Varshavsky Yanovsky, Y. Shestovska, J. Pei, N. Mackrides, H. Fung, R. Nejati (*Philadelphia-PA*)

P27

HIGH DOSE CYCLOPHOSPHAMIDE AS MOBILIZATION REGIMEN IN NEWLY DIAGNOSED MULTIPLE MYELOMA: SAFETY AND EFFICACY IN AN OUTPATIENT SETTING. SINGLE CENTER EXPERIENCE

L. Massarotti, A. Branca, L. Pavan, A. Maroccia, C.A. Cavarretta, V. Ruocco, I. Zatta, G. Scapinello, F. Piazza, F. D'Amore, F. Lessi, C. Gurrieri, R. Zambello, L. Trentin, T. Bero (*Padova-IT*)

3. RELAPSED/REFRACTORY MULTIPLE MYELOMA

P28

EFFICACY AND SAFETY OF CILTACABTAGENE AUTOLEUCEL (CILTA-CEL) IN PATIENTS WITH PROGRESSIVE MULTIPLE MYELOMA (MM) AFTER EXPOSURE TO NON-CELLULAR ANTI-B-CELL MATURATION ANTIGEN (BCMA) IMMUNOTHERAPY

N. van de Donk, M.V. Mateos, Y.C. Cohen, P. Rodriguez-Otero, B. Paiva, A.D. Cohen, T. Martin, A. Suvannasankha, D. Madduri, C. Corsale, J.M. Schecter, K.C. De Braganca, C.C. Jackson, H. Varsos, W. Deraedt, T. Rocca, P. Mistry, X. Xu, K. Li, E. Zudaire, M. Akram, L. Pacaud, I. Avivi, J. San-Miguel (*Amsterdam-NL, Salamanca-ES, Tel Aviv-IL, Pamplona-ES, Philadelphia-USA, San Francisco-USA, Indianapolis-USA, New York-USA, Raritan-USA, Beerse-BE, High Wycombe-UK, Springhouse-USA, Piscataway-USA*)

P29

PHASE 1/2 RESULTS OF TALQUETAMAB, A G PROTEIN-COUPLED RECEPTOR FAMILY C GROUP 5 MEMBER D X CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) (MONUMENTAL-1)

M.C. Minnema, A. Chari, C. Touzeau, C. Schinke, J. Berdeja, A. Oriol, N. WCJ V.D. Donk, P.R. Otero, E. Askari, M.V. Mateos, L.J. Costa, J. Caers, L. Rasche, A. Krishnan, D. Vishwamitra, X. Ma, X. Qin, K.S. Gries, M. Campagna, T. Masterson, B. Hilder, J. Tolbert, T. Renaud, J.D. Goldberg, C. Heuck, J.S. Miguel, P. Moreau (*Utrecht-NL, New York-USA, Nantes-FR, Little Rock-USA, Nashville-USA, Barcelona-ES, Amsterdam-NL, Pamplona-ES, Madrid-ES, Salamanca-ES, Birmingham-USA, Liege-BE, Würzburg-DE, Duarte-USA, Spring House-USA, Raritan-USA, Madrid-ES*)

P30

SINGLE COHORT RESULTS FROM MAJESTEC-2: TECLISTAMAB (TEC) IN COMBINATION WITH SUBCUTANEOUS DARATUMUMAB (DARA) AND LENALIDOMIDE (LEN) IN PATIENTS WITH MULTIPLE MYELOMA (MM)

E. Searle, H. Quach, S. Wong, L. Costa, C. Hulin, W. Janowski, J. Berdeja, S. Anguille, J. Matous, C. Touzeau, A. Michallet, M. Husnik, D. Vishwamitra, Z. Niu, J. Larsen, L. Chen, J. Goldberg, R. Popat, A. Spencer (Manchester-UK, Melbourne-AUS, San Francisco-USA, Birmingham-USA, Pessac-FR, Waratah-AUS, Nashville-USA, Edegem-BE, Denver-USA, Nantes-FR, Lyon-FR, San Diego-USA, Spring House-USA, Shanghai-CN, Los Angeles-USA, Raritan-USA, London-UK, Melbourne-AUS)

P31

SINGLE-AGENT BELANTAMAB MAFODOTIN IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA: FINAL ANALYSIS OF THE DREAMM-2 TRIAL

A. Nooka, A. Cohen, H. Lee, A. Badros, A. Suvannasankha, N. Callander, A. Abdallah, S. Trudel, A. Chari, E. Libby, M. Chaudhry, M. Hultcrantz, K.M. Kortüm, P. Richardson, R. Popat, D. Sborov, S. Hakim, E. Lewis, B. Bhushan, B. Gorsh, I. Gupta, J. Opalinska, S. Lonial (Atlanta-USA, Philadelphia-USA, Houston-USA, Baltimore-USA, Indianapolis-USA, Madison-USA, Kansas City-USA, Toronto-CAN, New York-USA, Seattle-USA, Washington-USA, Würzburg-DE, Boston-USA, London-UK, Salt Lake City-USA, Upper Providence-USA, Research Triangle Park-USA, Bangalore-IN)

P32

MAJESTEC-1: CORRELATIVE ANALYSES OF TECLISTAMAB, A B-CELL MATURATION ANTIGEN (BCMA) X CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)

N. van de Donk, D. Cortes-Selva, T. Casneuf, D. Vishwamitra, S. Stein, T. Perova, E. Ramos, L. Van Steenberg, R. Boominathan, O. Lau, C. Davis, A. Banerjee, T. Stephenson, C. Uhlar, R. Kobos, J. Goldberg, L. Pei, D. Trancucci, S. Girgis, S.X.W. Lin, L.S. Wu, P. Moreau, S. Usmani, N.J. Bahlis, R. Verona (Amsterdam-NL, Spring House-USA, Beerse-BE, Ghent-BE, Raritan-USA, South San Francisco-USA, Nantes-FR, New York-USA, Calgary-CAN)

P33

EFFECTIVENESS AND SAFETY OF BELANTAMAB MAFODOTIN IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA IN REAL-LIFE SETTING: THE ALFA STUDY

M. Roussel, N. Texier, R. Germain, S. Sapra, P. Paka, N. Kerbouche, X. Colin, X. Leleu (Limoges-FR, Paris-FR, Upper Providence-USA, Rueil-Malmaison-FR, Poitiers-FR)

P34

LIGHTHOUSE (OP-108): MELFLUFEN PLUS DARATUMUMAB (DARA) AND DEXAMETHASONE (DEX) VERSUS DARA IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) REFRACTORY TO AN IMMUNOMODULATORY DRUG (IMiD) AND A PROTEASOME INHIBITOR (PI) OR HAD RECEIVED ≥ 3 PRIOR LINES OF THERAPY INCLUDING AN IMiD AND A PI

M. Mateos, M. Szarejko, J. Bila, F. Schjesvold, I. Spicka, V. Maisnar, A. Jurczynszyn, Z. Grudeva-Popova, R. Hajek, G. Usenko, M. Thuresson, S. Norin, S. Jarefors, P. Richardson, L. Pour (Salamanca-ES, Gdansk-PL, Belgrade-RS, Oslo-NO, Prague-CZ, Hradec Kralove-CZ, Kraków-PL, Plovdiv-BG, Ostrava-CZ, Dnipro-UA, Stockholm-SE, Boston-USA, Brno-CZ)

P35

ANALYSIS OF DARATUMUMAB CLINICAL TRIALS: CHARACTERISTICS AND OUTCOMES IN PATIENTS WITH LENALIDOMIDE-REFRACTORY RELAPSED/REFRACTORY MULTIPLE MYELOMA TREATED WITH 1-3 PRIOR LINES OF THERAPY

H. Einsele, B. Dhakal, J.M. Schechter, T. Rocca, W. Deraedt, N. Lendvai, A. Slaughter, C. Lonardi, K. Connors, K. Qi, A. Londhe, R. Carson, J. Voelker, P. Cost, S. Valluri, E. Florendo, L. Pacaud, K. Yong (Würzburg-DE, Milwaukee-USA, Raritan-USA, Beerse-BE, Zug-CH, Buenos Aires-AR, Titusville-USA, Wayne-USA, Horsham-USA, Piscataway-USA, London-UK)

P36

BELANTAMAB MAFODOTIN IN PATIENTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA WHO HAVE RECEIVED AT LEAST ONE PROTEASOME INHIBITOR, ONE IMMUNOMODULATORY AGENT AND ONE ANTI-CD38 MONOCLONAL ANTIBODY: A RETRO-PROSPECTIVE ITALIAN OBSERVATIONAL STUDY

M. Offidani, S. Morè, M. Cavo, D. Derudas, F. Di Raimondo, A. Cuneo, L. Baldini, R. Della Pepa, M. Musso, M. Boccadoro, P. Musto, A. Belotti, F. Fioritoni, N. Di Renzo, A. Mele, B. Gamberi, L. De Paoli, R. Zambello, S. Grammatico, M. Brociner, F. Fazio, M.T. Petrucci (Ancona, Bologna, Cagliari, Catania, Ferrara, Milano, Napoli, Palermo, Torino, Bari, Brescia, Pescara, Lecce, Tricase, Reggio Emilia, Novara, Padova, Prato, Varese, Roma-IT)

P37

MULTIPLE MYELOMA MONITORING FROM ARCHIVED SERUM PROTEIN ELECTROPHORESIS GELS BY MASS SPECTROMETRY AND DE NOVO SEQUENCING

S. Noori, M. Zajec, H. Russcher, A.N. Tintu, A. Broijl, J.F.M. Jacobs, T.M. Luider, Y.B. de Rijke, M.M. van Duijn (Rotterdam-NL, Nijmegen-NL)

P38

PATIENT-REPORTED OUTCOMES (PRO) IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) TREATED WITH MELFLUFEN AND DEXAMETHASONE (DEX) OR POMALIDOMIDE (POM) AND DEX: ANALYSES FROM THE PHASE 3 OCEAN STUDY

F. Schjesvold, H. Ludwig, S. Delimpasi, P. Robak, M. Mateos, A. Sandberg, M. Thuresson, S. Norin, P. Richardson, P. Sonneveld (Oslo-NO, Vienna-AT, Athens-GR, Ostrava-CZ, Salamanca-ES, Stockholm-SE, Boston-USA, Rotterdam-NL)

P39

DEDALO: PHASE II STUDY OF DARATUMUMAB PLUS POMALIDOMIDE AND DEXAMETHASONE (DPD) IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA AND 17P DELETION
V. Montefusco, A.M. Cafro, G. Margiotta Casaluci, F. Patriarca, R. Mina, M. D'Agostino, A. Capra, C. Priola, B. Dalla Palma, R. Rizzi, A. Genua, M.T. Petrucci, L. Paris, A. Belotti, M. Cavo, C. Conticello, C. Carlo-Stella, M. Boccadoro (Milano, Pavia, Udine, Torino, Parma, Bari, Terni, Roma, Bergamo, Brescia, Bologna, Catania, Rozzano-IT)

P40

REAL-WORLD TREATMENT PATTERNS OF PATIENTS INITIATING THIRD-LINE THERAPY IN RELAPSED/REFRACTORY MULTIPLE MYELOMA IN EUROPE
M. Lehne, K.M. Kortüm, E. Zamagni, T. d'Estrube, S. Shukla, E. Zhuleku, M. Ghiani, M. Hanna, U. Maywald, T. Wilke, S. Perera (Berlin-DE, Würzburg-DE, Bologna-IT, London-UK, Upper Providence-USA, Wismar-DE, Dresden-DE)

P41

NO EVIDENCE OF B-CELL MATURATION ANTIGEN (BCMA) EXPRESSION LOSS OR SYSTEMIC IMMUNE IMPAIRMENT AFTER TREATMENT WITH THE BCMA-TARGETED ANTIBODY-DRUG CONJUGATE BELANTAMAB MAFODOTIN IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA
D.E. Lowther, E.A. Houseman, G. Han, E. Kleanthous, D. Knoblock, X. Zhou, S. Banerjee, S. Patel, D. Figueroa (Stevenage-UK, Upper Providence-USA, Bengaluru-IN)

P42

HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA TREATED WITH TALQUETAMAB, A G PROTEIN-COUPLED RECEPTOR FAMILY C GROUP 5 MEMBER D X CD3 BISPECIFIC ANTIBODY, FROM MONUMENTAL-1
N. Van de Donk, L. Rasche, C. Touzeau, A. Chari, C. Schinke, M. Minnema, J. Berdeja, A. Oriol, P. Rodriguez-Otero, E. Askari, M. Mateos, L. Costa, J. Caers, A. Krishnan, D. Vishwamitra, J. Ma, X. Qin, K.S. Gries, K. Kato, M. Campagna, T. Masterson, B. Hilder, J. Tolbert, T. Renaud, J. Goldberg, C. Heuck, P. Moreau, J. San-Miguel (Amsterdam-NL, Würzburg-DE, Nantes-FR, New York-NY, Little Rock-USA, Utrecht-NL, Nashville-TE, Badalona-ES, Pamplona-ES, Madrid-ES, Salamanca-ES, Birmingham-USAL, Liège-BE, Duarte-USA, Spring House-USA, Raritan-USA)

P43

CIRCULATING CLONAL PLASMA CELLS AT START OF SALVAGE REGIMEN PROVIDE POWERFUL PROGNOSTICATION BIOMARKER IN MULTIPLE MYELOMA PATIENTS AT FIRST RELAPSE
A. Romano, N.L. Parrinello, G. Scandura, S. Marino, A. Triolo, V. Del Fabro, F. Di Raimondo, C. Conticello (Catania-IT)

P44

DETECTION OF SOLUBLE BCMA IN TEARS OF MM PATIENTS TREATED WITH BELANTAMAB MAFODOTIN
U. Munawar, J. Theuersbacher, L. Haertle, X. Zhou, S. Han, A. Regensburger, J. Mersi, M. Bittrich, F. Seifert, M.S. Haider, S. Nerreter, C. Vogt, E. Teufel, H. Einsele, L. Rasche, D. Kampik, K.M. Kortüm (Wuerzburg-DE, Madrid-ES)

P45

HIGH-DOSE CARFILZOMIB ACHIEVES SUPERIOR ANTI-TUMOR ACTIVITY OVER LOW-DOSE AND RECAPTURES RESPONSE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA RESISTANT TO LOW-DOSE CARFILZOMIB BY CO-INHIBITING THE B2 AND B1 PROTEASOME SUBUNITS
X. Zhou, A. Besse, J. Peter, M.J. Steinhardt, C. Vogt, S. Nerreter, E. Teufel, E. Stanojkovska, X. Xiao, H. Hornburger, L. Haertle, M. Mendez Lopez, U. Munawar, A. Riedel, S. Han, E. Maurits, H.S. Overkleef, B. Florea, H. Einsele, K.M. Kortüm, C. Driessen, L. Besse, L. Rasche (Wuerzburg-DE, St Gallen-CH, Leiden-NL)

P46

SEER-MEDICARE DATABASE: REAL-WORLD TREATMENTS AND OUTCOMES IN PATIENTS WITH LENALIDOMIDE-REFRACTORY RELAPSED MULTIPLE MYELOMA TREATED WITH 1-3 PRIOR LINES OF THERAPY, INCLUDING A PI AND IMID
H. Einsele, B. Dhakal, R. Potluri, J. Schechter, W. Deraedt, N. Lendvai, A. Slaughter, C. Lonardi, S. Nair, J. He, J. Voelker, P. Cost, S. Vallur, F. Yalniz, L. Pacaud, K. Yong (Würzburg-DE, Milwaukee-USA, New York-USA, Raritan-NJ, Beerse-BE, Zug-CH, Buenos Aires-AR, Horsham-USA, Piscataway-USA, London-UK)

P47

REAL-WORLD DATA OF ATTRITION RATES BY SUBSEQUENT LINES OF THERAPY IN MULTIPLE MYELOMA PATIENTS TREATED IN A TERTIARY CARE ITALIAN CENTRE
S. Morè, M. Offidani, L. Corvatta, V.M. Manieri, A. Olivieri (Ancona, Fabriano-IT)

P48

CARFILZOMIB, LENALIDOMIDE AND DEXAMETHASONE IN RELAPSED REFRACTORY MULTIPLE MYELOMA: A PROSPECTIVE REAL-LIFE EXPERIENCE OF THE REGIONAL TUSCAN MYELOMA NETWORK (RTM)
I. Attucci, E. Antonioli, S. Pileri, G. Buda, A. Gozzetti, V. Candi, F. Simonetti, M.L. Del Giudice, S. Ciofini, M. Staderini, S. Grammatico, A. Buzzichelli, M. Messeri, M. Bocchia, S. Galimberti, A.M. Vannucchi (Firenze, Pisa, Siena, Arezzo, Lido di Camaiore, Prato-IT)

P49

A REAL-WORLD RETROSPECTIVE-PROSPECTIVE ANALYSIS OF EFFICACY AND SAFETY OF COMBINED IXAZOMIB, LENALIDOMIDE AND DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA: THE NORTHERN ITALY EXPERIENCE

A. Furlan, M. Cea, R. Zambello, L. Pavan, M. Galli, C. Clissa, S. Mangiacavalli, A. Cafro, S. Girlanda, F. Patriarca, C. Minotto, G. Bertoldero, G. Barila, A. Pascarella, A. Lico, R. Paolini, N. Rabassi, N. Pescosta, M. Porrizzo, G. De Sabbata, A. Pompa, G. Bega, S. Cavallin, F. Guidotti, G. Semenzato, C. Zaina, F. Gherlinzoni (*Firenze, Pisa, Siena-IT*)

P50

OVERALL SURVIVAL ADVANTAGE OF MONOCLONAL ANTIBODIES BASED-TREATMENTS IN MULTIPLE MYELOMA PATIENTS RELAPSED AFTER ALLOGENEIC STEM CELL TRANSPLANTATION

C. Nozzoli, M. Pucillo, M. Martino, L. Giaccone, A. Rambaldi, E. Benedetti, D. Russo, N. Mordini, P. Bernasconi, S. Mangiacavalli, P. Pioltelli, P. Carluccio, P. Galieni, M. Ladetto, S. Sica, M. Isola, M. De Martino, E. Oldani, E. Degrandi, A. Biasco, R. Fanin, R. Saccardi, F. Ciceri, F. Patriarca (*Firenze, Udine, Reggio Calabria, Torino, Bergamo, Milano, Pisa, Brescia, Cuneo, Pavia, Monza, Bari, Ascoli Piceno, Alessandria, Roma-IT*)

P51

EFFICACY AND SAFETY OF THIRD-LINE OR LATER TREATMENTS, INCLUDING THE CD38 MONOCLONAL ANTIBODY CLASS, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: A SYSTEMATIC LITERATURE REVIEW

M. Hanna, J. Chorazy, I. Iheanacho, B. Gorsh, P.F. Wang, P. Paka, S. Perera (*Collegetown-USA, Evidera-UK, Philadelphia-USA, London-UK*)

4. SPECIAL CONDITIONS

P52

RISK STRATIFICATION COMBINING SKY92 GENE EXPRESSION PROFILING AND TRADITIONAL FISH IN MULTIPLE MYELOMA: THE FIRST PROSPECTIVE EVIDENCE IN THE R2-ISS ERA

X. Zhou, A. Hofmann, C. Vogt, S. Nerreter, E. Teufel, E. Stanojkowska, M. Truger, B. Engel, X. Xiao, F. Eisele, P. Weis, A. Barcic, J. Peter, C. Riedhammer, M.J. Steinhardt, H. Hornburger, S. Han, L. Haertle, U. Munawar, J. Mersi, C. Haferlach, H. Einsele, K.M. Kortüm, L. Rasche (*Würzburg-DE, Munich-DE*)

P53

REAL-WORLD TREATMENT SEQUENCES AND COSTS OF 96 PATIENTS WITH MULTIPLE MYELOMA FROM DIAGNOSIS TO DEATH

M.R. Seefat, D.G.J. Cucchi, K. Groen, M.L. Donker, K.G. van der Hem, M. Westerman, A.M. Gerrits, A. Beeker, N.W.C.J. van de Donk, H.M. Blommestein, S. Zweegman (*Amsterdam, Rotterdam, Zaandam, Alkmaar, Hoofddorp-NL*)

P54

ORAL ANTIVIRALS RITONAVIR-NIRMATRELVIR AND MOLNUPIRAVIR ARE HIGHLY EFFECTIVE IN PATIENTS WITH MULTIPLE MYELOMA AND COVID-19; A SINGLE-CENTER, PROSPECTIVE STUDY

V. Spiliopoulou, I. Ntanasis-Stathopoulos, P. Malandrakis, M. Gavriatopoulou, F. Theodorakakou, D. Fotiou, R.E. Syrigou, M. Migkou, M. Roussou, E. Eleutherakis-Papaiakovou, E. Kastritis, M.A. Dimopoulos, E. Terpos (*Athens-GR*)

P55

MULTIPLE MYELOMA AND SARS-COV-2 INFECTION: AN EUROPEAN HEMATOLOGY ASSOCIATION SURVEY (EPICOVIDEHA) OF 1,221 PATIENTS THROUGH THE DIFFERENT PHASES OF COVID-19 PANDEMIC

P. Musto, J. Salmanton-García, N. Sgherza, R. Bergantim, F. Farina, A. Glenthøj, G.C. Seval, B. Weinbergerová, V. Bonuomo, Y.M. Bilgin, L. Rahimli, F. Marchesi, O.A. Cornely, L. Pagano (*Bari, Cologne-DE, Porto-PT, Milano-IT, Copenhagen-DK, Ankara-TR, Brno-CR, Verona-IT, Torino-IT, Goes-NL, Roma-IT*)

P56

SURVIVAL BENEFIT OF BIRTAMIMAB IN MAYO STAGE IV AL AMYLOIDOSIS IN THE PHASE 3 VITAL STUDY WAS CONSISTENT ACROSS ALL KEY BASELINE VARIABLES

M. Gertz, A. Cohen, R. Comenzo, E. Kastritis, H. Landau, E. Libby, M. Liedtke, A. Wechalekar, Y. Ando, Y. Koh, J. Zonder, G. Palladini, C. Nie, C. Karp, Y. Jin, A. Conrad, G. Kinney, G. Merlini (*Rochester-USA, Philadelphia-USA, Boston-USA, Athens-GR, New York-USA, Seattle-USA, Stanford-USA, Heidelberg-DE, London-UK, Sasebo-JP, Seoul-KR, Detroit-USA, Pavia-T, South San Francisco-USA*)

P57

PRE-EXPOSURE PROPHYLAXIS FOR COVID-19 WITH TIXAGEVIMAB/CILGAVIMAB (EVUSHELD) IN PATIENTS WITH MULTIPLE MYELOMA

I. Ntanasis-Stathopoulos, M. Gavriatopoulou, E. Eleutherakis-Papaiakovou, P. Malandrakis, V. Spiliopoulou, R.E. Syrigou, F. Theodorakakou, D. Fotiou, M. Migkou, M. Roussou, E. Kastritis, M.A. Dimopoulos, E. Terpos (*Athens-GR*)

P58

LOW CD38 EXPRESSION BY PLASMA CELLS IN EXTRAMEDULLARY DISEASE IN MULTIPLE MYELOMA PATIENTS

L. Notarfranchi, F. Accardi, B. Dalla Palma, C. Mancini, E. Martella, S. Bonomini, P. Storti, D. Toscani, J. Burroughs, V. Marchica, G. Sammarelli, N. Giuliani (*Parma, Palermo-IT*)

P59

ACTIVE TREATMENT AND LOW IGM ARE ASSOCIATED WITH INFERIOR SARS-COV-2 SPIKE ANTIBODY RESPONSE TO THREE DOSES OF COVID-19 RNA VACCINATION IN PATIENTS WITH MULTIPLE MYELOMA

A. Duminuco, A. Romano, D. Leotta, E. La Spina, D. Cambria, A. Bulla, V. Del Fabro, D. Tibullo, C. Giallongo, G.A. Palumbo, C. Conticello, F. Di Raimondo (*Catania-IT*)

P60

EVOLVING OUTCOMES OF EXTRAMEDULLARY DISEASE IN MULTIPLE MYELOMA: 20-YEARS SINGLE CENTER EXPERIENCE

F. Palumbo, A. Orofino, V. Del Fabro, M. Fazio, F. Elia, B. Esposito, S. Frazzetto, A. Romano, F. Di Raimondo, C. Conticello (*Catania-IT*)

P61

TRENDS IN AL AMYLOIDOSIS: DECREASE IN EARLY MORTALITY, INCREASE IN SURVIVAL BUT LESS AHCT: SINGLE CENTER EXPERIENCE

H. Yilmaz, G.C. Seval, B. Karakaya, G.Y. Ermis, M. Aydogan, S.C. Bozdag, S.K. Toprak, M.K. Yuksel, P. Topcuoglu, O. Arslan, M. Ozcan, O. Ilhan, M. Beksac (*Ankara-TR*)

P62

USE OF ANTIVIRAL FOR PAUCISINTOMATIC COVID-19 INFECTION IN MULTIPLE MYELOMA PATIENTS UNDERGOING TREATMENT

O. Annibali, F. Fazio, M. Di Cecca, C. Liberatore, F. Pisani, L. De Padua, V. Tomarchio, R. Poggiali, F. Fioritoni, M.T. Tafuri, F. Viola, G. Montanaro, M. Passucci, S. Pulini, M.T. Petrucci, L. Rigacci (*Roma, Pescara, Frosinone-IT*)

P63

BREAKTHROUGH COVID-19 IN FULL VACCINATED PATIENTS WITH MULTIPLE MYELOMA: A SINGLE CENTER EXPERIENCE OF 54 PATIENTS

N. Sgherza, P. Curci, R. Rizzi, A. Perfetto, O. Battisti, N. Pizzileo, G. De Trizio, P. Musto (*Bari-IT*)

P64

A CASE OF COVID-19 PNEUMONIA AFTER CAR T-CELL THERAPY IN A PATIENT AFFECTED BY RELAPSED/REFRACTORY MULTIPLE MYELOMA

C. Ielo, F. Fazio, S. Rocchi, I. Rizzello, E. Zamagni M.T. Petrucci (*Roma, Bologna-IT*)

ABSTRACT REVIEWERS

Meral

Niccolò

Annemiek

Jo

Thomas

Mattia

Martin

Efstathios

Heinz

Roberto

Monique

Inger S.

Leo

Fredrik Hellem

Cyrille

Katja Christina

Beksac

Bolli

Broijl

Caers

Cupedo

D'Agostino

Kaiser

Kastritis

Ludwig

Mina

Minnema

Nijhof

Rasche

Schjesvold

Touzeau

Weisel

Ankara, Turkey

Milan, Italy

Rotterdam, The Netherlands

Liège, Belgium

Rotterdam, The Netherlands

Turin, Italy

London, United Kingdom

Athens, Greece

Wien, Austria

Turin, Italy

Utrecht, The Netherlands

Amsterdam, The Netherlands

Würzburg, Germany

Oslo, Norway

Nantes, France

Hamburg, Germany

4th European Myeloma Network Meeting



MEETING VENUE

Beurs van Berlage

Damrak 243, 1012 ZJ

Amsterdam, The Netherlands

Ph +31 20 530 4141

www.beursvanberlage.com

SCIENTIFIC PROGRAM COORDINATORS

Pieter Sonneveld - *Local Organizer (The Netherlands)*

Sonja Zweegman - *Local Organizer (The Netherlands)*

Mario Boccadoro (*Italy*)

Niels van de Donk (*The Netherlands*)

Francesca Gay (*Italy*)

Roberto Mina (*Italy*)

THE EMN BOARD

Pieter Sonneveld (*The Netherlands*)

Mario Boccadoro (*Italy*)

Gordon Cook (*United Kingdom*)

Meletios Athanasios Dimopoulos (*Greece*)

Hermann Einsele (*Germany*)

Roman Hajek (*Czech Republic*)

Heinz Ludwig (*Austria*)

Philippe Moreau (*France*)

Jesus Fernando San-Miguel (*Spain*)

Fredrik Schjesvold (*Norway*)

ORGANIZING SECRETARIAT

Studio E.R. Congressi

Via De' Poeti 1/7 - 40124 Bologna - Italy

Ph +39 051 4210559 - Fax +39 051 4210174

E-mail: emnmeeting@ercongressi.it

www.ercongressi.it

Amsterdam
April 20-22, 2023

Beurs van Berlage